Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2012
February 2012, Vol 3, No 1
February 2012, Vol 3, No 1
Bevacizumab Delays Progression, May Extend Survival in Ovarian Cancer
In the Literature
February 2012, Vol 3, No 1
Two phase 3 international clinical studies show that initiating therapy with bevacizumab in combination with standard chemotherapy extends progression-free survival (PFS) in women with advanced ovarian cancer, and women at high risk for disease progression may live longer with the addition of bevacizumab to standard therapy (Burger RA, et al. N Engl J Med. 2011;365:2473-2483; Perren TJ, et al. N Engl J Med. 2011;365:2484-2496).
Read Article
Pertuzumab Prolongs PFS in Patients with HER2 Metastatic Breast Cancer
In the Literature
February 2012, Vol 3, No 1
he addition of pertuzumab to trastuzumab and docetaxel as first-line therapy for women with HER2-positive metastatic breast cancer significantly prolongs progression-free survival (PFS) compared with the use of the 2 agents without pertuzumab, according to results of a new phase 3 clinical trial (Baselga J, et al. N Engl J Med. 2012;366:101-119).
Read Article
Which Patients with Prostate Cancer Should Receive Hormone Therapy in Addition to Radiation?
By
Phoebe Starr
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
February 2012, Vol 3, No 1
Read Article
Physician-Led Approach Can Cut Unnecessary Testing in Prostate Cancer
By
Caroline Helwick
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
February 2012, Vol 3, No 1
Feedback from their peers helped physicians refrain from ordering unnecessary tests for patients with newly diagnosed cancer, according to a recent study (Miller DC, et al. J Urol. 2011;186:844-849. Epub 2011 Jul 23).
Read Article
Array of Treatments for Metastatic Prostate Cancer, but Can We Afford Them?
By
Phoebe Starr
Genitourinary Cancers Symposium
February 2012, Vol 3, No 1
New York, NY—Men with castration-resistant prostate cancer (CRPC) now have several different treatments that improve their survival—docetaxel (Taxo-tere), cabazitaxel (Jevanta), abiraterone (Zytiga), and sipuleucel-T (Provenge).
Read Article
Two Mechanistically Distinct Agents Lead to Impressive Survival Improvements in Advanced Prostate Cancer
Genitourinary Cancers Symposium
February 2012, Vol 3, No 1
San Francisco, CA—Two treatments significantly extended survival in men with metastatic castration-resistant prostate cancer (CRPC) in separate phase 3 clinical trials reported at the 2012 Genitourinary Cancers Symposium.
Read Article
Comparative Effectiveness Analysis of 3 Radiation Therapies for Prostate Cancer
By
Wayne Kuznar
Genitourinary Cancers Symposium
February 2012, Vol 3, No 1
San Francisco, CA—A new, large comparative effectiveness analysis of 3 techniques for delivering radiation therapy for the treatment of localized prostate cancer supports intensity-modulated radiation therapy (IMRT) as the current standard, said Ronald Chen, MD, MPH, Assistant Professor of Radiation Oncology, University of North Carolina (UNC), Chapel Hill, and Research Fellow, Sheps Center for Health Services Research, UNC at the 2012 annual Genitourinary Cancers Symposium.
Read Article
Americans Willing to Pay Hundreds of Dollars Out of Pocket for Cancer Risk Tests
By
Rosemary Frei, MSc
Health Policy
,
Policies & Guidelines
February 2012, Vol 3, No 1
American adults would be willing to pay a median of $263 for a perfect prostate cancer prediction test and $232 for a perfect breast cancer prediction test, according to a recent survey (Neumann PJ, et al. Health Econ. 2012;21:238-251).
Read Article
Direct-to-Consumer Genetic Testing: Concerns Trump Benefits at This Point
By
Caroline Helwick
Health Policy
,
Policies & Guidelines
February 2012, Vol 3, No 1
Miami, FL—Direct-to-consumer (DTC) marketing of genetic tests represents personalized medicine in evolution. High-throughput genetic technologies have made it possible to evaluate individuals at a relatively affordable price, but a number of technologic, social, regulatory, and ethical issues must first be settled before DTC genetic testing takes personalized medicine to new heights.
Read Article
Eribulin Associated with Less Neuropathy than Ixabepilone
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
February 2012, Vol 3, No 1
San Antonio, TX—In a randomized phase 2 study of patients with metastatic breast cancer, peripheral neuropathy was less likely to occur in patients receiving eribulin mesylate than with ixabepilone.
Read Article
Page 2 of 5
1
2
3
4
5
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma